🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Alibaba weighs appeal against HK panel ruling that healthcare deal broke takeover code

Published 04/26/2016, 12:28 AM
Updated 04/26/2016, 12:30 AM
© Reuters. A logo of Alibaba Group is pictured at its headquarters in Hangzhou
HK50
-
HSI
-
BABA
-
0241
-

HONG KONG (Reuters) - Chinese e-commerce giant Alibaba Group Holding Ltd (N:BABA) said it's considering whether to launch an appeal against a Hong Kong regulator's finding that it breached takeover rules by buying an effective majority stake in a healthcare firm in 2014 without extending the offer to all of its shareholders.

Alibaba said late on Monday that the Hong Kong Takeovers and Mergers Panel, part of city's Securities and Futures Commission (SFC) watchdog, found it broke rules by arranging a deal with certain investors in CITIC 21CN, now known as Alibaba Health Information Technology Ltd (HK:0241), at beneficial terms not extended to other shareholders.

The SFC ruled that the breach of code in the 2014 investment meant an original waiver to a requirement to launch a general offer to all investors was invalidated, Alibaba said. But the e-commerce firm said the regulator issued a new waiver in view of the sharp rise in Alibaba Health stock since 2014, meaning Alibaba is not currently required to launch a full buyout.

Alibaba said in the statement it believes it fully complied with the takeover code regarding the investment, worth $170 million at the time, which gave it a 54 percent stake in the healthcare business after buying newly issued shares in the company.

Alibaba noted it was granted a waiver by the full offer requirement, given that the stock has soared more than six-fold since the 2014 offer.

Shares in Alibaba Health slid 9.6 percent in early trading on Tuesday, valuing the company at about $5.4 billion, while the benchmark Hang Seng index (HSI) fell 0.8 percent.

An Alibaba spokesman said the firm is considering appealing against the SFC ruling but declined to elaborate further when contacted by Reuters on Tuesday.

"Alibaba Group believes that the determination by the panel will not affect Alibaba Health's operations and it intends that Alibaba Health will continue to be the flagship healthcare subsidiary of Alibaba Group," the e-commerce firm said in its statement.

© Reuters. A logo of Alibaba Group is pictured at its headquarters in Hangzhou

In a separate statement issued late on Monday, Alibaba Health said the company continues to maintain its normal business operations.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.